OakChart

Intercure Ltd

INCRHealthcare·Drug Manufacturers - Specialty & Generic·Israel·Micro·NASD·Nov 11 • 3:59 PM ET

3.91+0.31 (8.61%)
2026-11-12 05:48 CET
Market cap
50.72 USD m
Revenue, TTM
78.55 USD m
Net income, TTM
-10.76 USD m
Free cash flow, TTM
-1.45 USD m
EPS diluted, TTM
-1.00
P/E
-
Compare

Price

INCR against its 20, 50 and 200-day averages
2050200
3.004.005.006.00292K585KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INCRclose 3.9120-day 4.1350-day 4.81200-day 4.583.9152w low

48.2% under the 52-week high of 7.55 on 17 Dec 2025. 52-week low 3.12 on 5 Nov 2026. Last 15 sessions, 48.4% high to low

Volume 3.60× normal · the line is the 50-bar volume average

Profile

INCR
52-week range, 18% of the way up
3.127.55

InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies in the Biomed Sector and Investments in the Medical Cannabis Sector segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

Employees285
IPOJan 28, 2019
Beta1.53
ATR, 14d0.31
Rel volume3.60
Short float0.06%
Insider own39.17%
Inst own2.81%

Snapshot

6 groups

Valuation

Index-
Market Cap50.71M
Enterprise Value92.80M
Income-10.76M
Sales78.55M
Book/sh11.38
Cash/sh1.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees285
IPOJan 28, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S0.65
P/B0.34
P/C3.32
P/FCF-
EV/EBITDA-
EV/Sales1.18
Quick Ratio0.95
Current Ratio1.48
Debt/Eq0.46
LT Debt/Eq0.20
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.00
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- 14.69%
Sales past 3/5Y-12.19% 32.88%
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-71.12%
Sales Q/Q-1.48%
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own39.17%
Insider Trans0.00%
Inst Own2.81%
Inst Trans-2.27%
ROA-
ROE-
ROIC-7.21%
Gross Margin8.70%
Oper. Margin-27.06%
Profit Margin-13.69%
SMA20-5.33%
SMA50-18.75%
SMA200-14.61%
Trades-

Technical

Shs Outstand9.11M
Shs Float7.89M
Short Float0.06%
Short Ratio0.19
Short Interest0.00M
52W High7.55 -48.21%
52W Low3.12 25.32%
Volatility11.73% 6.78%
ATR (14)0.31
RSI (14)41.77
Beta1.53
Rel Volume3.60
Avg Volume23.56K
Volume84,836

Performance

Perf Week8.31%
Perf Month-22.27%
Perf Quarter-15.57%
Perf Half Y-4.63%
Perf YTD-14.07%
Perf Year-44.54%
Perf 3Y-26.92%
Perf 5Y-90.06%
Perf 10Y-
Recom1.00
Target Price7.17
Prev Close3.60
Price3.91
Change %8.61%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
May 18, 2022UpgradeCCanaccord GenuitySpeculative Buy → Buy$13+232.5%

Peers

Mkt cap
TickerCompanyMkt cap
IMCCIM Cannabis Corp0.95M
ACBAurora Cannabis Inc331.99M
TLRYTilray Brands Inc385.73M
CRONCronos Group Inc1.26B
OGIOrganigram Global Inc120.38M
CGCCanopy Growth Corp256.13M
HITIHigh Tide Inc225.52M
TRLVTrulieve Cannabis Corp2.16B
CPIXCumberland Pharmaceuticals Inc91.70M
SNDLSNDL Inc345.52M

News

latest 14 of 186
  • InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
  • InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages (GlobeNewswire) +28.71%
  • InterCure Ltd. Announces 1-for-5 Reverse Share Split (GlobeNewswire)
  • InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds (GlobeNewswire) +17.37%
  • InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition (GlobeNewswire) +9.27%
  • InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow (GlobeNewswire) +5.45%
  • InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement (GlobeNewswire)
  • InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million (GlobeNewswire) -5.78%
  • InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation (GlobeNewswire)
  • InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow (GlobeNewswire)
  • InterCure Enters Premium US Cannabis Market With ISHI Deal (Benzinga)
  • InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands (GlobeNewswire)
  • InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 (PR Newswire)
  • InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q32024-11-12-0.054-0.0530.11020.3020.051
2024S12024-08-290.041--34.51--
2024Q12024-05-13-0.177-0.10614.83--
2023Q42024-05-01-2.151-0.10811.83-1
2023Q22023-08-31-0.068-26.8530.711
2023Q12023-05-150.0070.0560.00729.0329.151
2025Q1--0.108--24.501
2025Q2--0.162--25.311
2025Q3--0.243--28.271
2025Q4--0.269--28.811
2024Q4--0.041--22.541

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1.740--2.13119.17-
2021FY0.2610.8120.17870.8569.07
2022FY1.539-1.469109.37-
2023FY-1.850--96.72-
2024FY--0.054-1.996-76.68
2025FY-0.781-0.963-106.97
2026FY-1.643--129.18

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2024Q4S2024-11-2510022.5422.5422.54
2024Q4S2024-11-1210122.3122.3122.31
2024Q4S2024-09-1110122.2622.2622.26
2024Q4S2024-05-2210026.0326.0326.03
2024Q4S2023-12-1910027.2327.2327.23
2024Q4S2023-12-1810027.2327.2327.23
2024Q4S2023-12-1710027.2327.2327.23
2024Q4S2023-12-1610027.2327.2327.23
2024Q4S2023-12-1310027.2327.2327.23
2024Q4S2023-12-1210027.2327.2327.23
2024Q4S2023-12-1110027.2327.2327.23
2024Q4S2023-12-1010027.2327.2327.23
2024Q4S2023-12-0910027.2327.2327.23
2024Q4S2023-12-0810027.2327.2327.23

Estimate history

EPS, annual-0.445-0.991-0.355-2.1310.1781.469-1.843-1.996-0.963
Period201720182019202020212022202320242025
EPS, quarterly-0.06-0.1080.4630.5080.2350.2690.007
PeriodQ3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Sales, annual002.50518.91168.009115.68296.40864.52378.336
Period201720182019202020212022202320242025
Sales, quarterly19.07525.26827.27328.48829.55930.25330.041
PeriodQ3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23
Shares, annual3.5123.714.8765.3889.0279.1159.1159.43310.936
Period201720182019202020212022202320242025
Shares, quarterly8.5349.0279.0279.0799.0799.1159.115
PeriodQ3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue78.5578.3464.5296.41115.6868.0118.912.510.00
Cost of Goods Sold Incl. D&A71.7173.2660.7369.0272.7442.6110.292.180.00
Gross Profit6.835.083.7927.3842.9425.408.620.33-0.00
Selling, General and Administrative Excl. Other28.0925.5226.3024.3328.3416.688.1023.632.73
Research and Development0.110.110.110.110.190.380.460.48-
Other Operating Expense-0.000.000.000.000.00-0.000.00
Operating Income-21.25-20.45-22.513.0614.608.720.51-23.31-2.73
Interest Expense5.795.756.166.794.451.561.150.550.29
Unusual Expense0.668.725.0519.533.942.6110.35-5.900.48
Net Income Before Taxes-13.37-12.87-23.59-16.6213.055.80-11.14-1.75-3.56
Income Taxes-2.20-2.12-3.930.610.033.54-0.66-0.190.00
Consolidated Net Income-11.08-10.66-19.66-17.2313.022.26-10.48-1.65-3.56
Net Income From Continuing Operations-10.76-10.35-18.31-16.8013.341.45-10.83-1.65-3.56
Net Income-10.76-10.35-18.31-16.8013.341.45-10.83-1.65-3.56
EPS (Recurring)-0.95-0.40-1.61-0.341.770.40-0.70-1.24-0.90
EPS (Basic, Before Extraordinaries)-1.00-0.96-2.00-1.841.470.19-2.13-0.35-0.99
EPS (Diluted)-1.00-0.96-2.00-1.841.470.18-2.13-0.35-0.99
EBITDA-16.27-15.48-18.356.6318.0811.011.46-23.07-2.73
Non-Operating Income (Expense)14.3422.0510.126.646.841.26-0.1516.22-0.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.550.540.470.542.041.542.2414.701.65
Price To Sales Ratio0.700.701.160.601.344.006.8444.63-
Gross Margin8.706.485.8828.4037.1237.3545.5813.07-
Operating Margin-27.06-26.10-34.883.1712.6212.822.72-930.34-
Net Margin-13.69-13.22-28.38-17.4311.532.13-57.25-66.02-
Shares Outstanding10.9410.949.439.119.119.035.394.883.71
Market Capitalization50.7250.7246.83------

Income statement, quarterly

Currency USD, millions
Metric2025S22025S12019S12018S12017S22017S12017S1
Total Revenue42.3836.16-1.240.000.000.000.00
Cost of Goods Sold Incl. D&A46.2825.44-0.670.000.000.000.00
Gross Profit-3.8910.73-0.58-0.000.00-0.00-0.00
Selling, General and Administrative Excl. Other16.5411.54-17.400.100.180.140.14
Research and Development0.060.05------
Other Operating Expense0.00---0.000.000.000.00
Operating Income-20.44-0.82--16.82-0.10-0.18-0.14-0.14
Interest Expense2.912.88-0.500.340.200.200.20
Unusual Expense1.10-0.44--8.210.910.440.390.39
Net Income Before Taxes-12.73-0.64-7.16-1.32-0.82-0.69-0.69
Income Taxes-2.07-0.13--0.190.000.000.000.00
Consolidated Net Income-10.57-0.50-7.26-1.32-0.82-0.69-0.69
Net Income From Continuing Operations-10.28-0.47-7.26-1.32-0.82-0.69-0.69
Net Income-10.28-0.47-7.26-1.32-0.82-0.69-0.69
EPS (Recurring)-0.88-0.08-0.29-0.19-0.15-0.13-0.01
EPS (Basic, Before Extraordinaries)-0.95-0.05-1.63-0.36-0.24-0.20-0.01
EPS (Diluted)-0.95-0.05-1.38-0.36-0.24-0.20-0.01
EBITDA-17.811.54--16.78-0.10-0.18-0.14-0.14
Non-Operating Income (Expense)11.712.62-16.280.03-0.000.03-
Stock Option Compensation Expense0.360.19-15.62----
Price To Sales Ratio0.70-------
Gross Margin-9.1929.66-46.47----
Operating Margin-48.22-2.25--1,352.71----
Net Margin-24.26-1.31-583.49----
Shares Outstanding10.949.43-4.813.643.513.32-
Market Capitalization50.7269.33------

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments15.2821.9530.8269.9269.9211.937.970.980.70
Short Term Receivables48.4749.5447.4336.8312.064.781.910.350.01
Inventories35.2835.6337.7036.1924.427.021.760.000.00
Other Current Assets0.360.410.360.891.600.140.580.000.00
Total Current Assets99.38107.53116.31143.83108.0123.8712.221.330.71
Net Property, Plant & Equipment32.2628.8827.0729.2327.7916.659.310.020.00
Total Investments and Advances0.320.595.6612.060.820.9811.558.266.17
Long-Term Note Receivable1.500.121.17------
Intangible Assets68.7761.6461.4080.5486.2059.2148.630.000.00
Deferred Tax Assets14.4310.536.855.850.97----
Other Assets0.000.000.000.000.000.900.000.000.00
Total Assets216.67209.29218.45271.51223.80101.6281.719.616.89
Short Term Debt Incl. Current Port. of LT Debt32.6520.3725.7837.5224.290.794.013.420.84
Accounts Payable21.3821.2821.7835.7320.725.801.430.06-
Other Current Liabilities13.2320.5815.1615.3817.202.711.120.870.10
Total Current Liabilities67.2662.2362.7388.6362.209.316.554.350.94
Long Term Debt24.7737.6528.5634.8010.711.290.930.000.00
Provision for Risks Charges0.280.270.230.290.070.050.060.00-
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities92.31100.1591.52123.7272.9810.647.544.350.94
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity124.41108.95126.39142.07143.9585.4974.115.265.95
Total Shareholders Equity124.41108.95126.39142.07143.9585.4974.115.265.95
Accumulated Minority Interest-0.050.190.545.726.875.480.070.000.00
Total Equity124.36109.14126.93147.79150.8290.9874.185.265.95
Total Liabilities & Stockholders Equity216.67209.29218.45271.51223.80101.6281.719.616.89
Book Value Per Share11.3811.5513.8715.5915.9515.8715.201.421.69
Tangible Book Value Per Share5.095.027.136.756.404.885.231.421.69
Full-Time Employees285320---100175767
Price to Book Ratio0.340.37-------
Return on Assets-4.86-8.56-6.865.420.89-11.81-3.62-43.14-21.46
Return on Equity-8.87-15.56-12.529.331.27-13.57-4.17-63.50-24.79
Return on Invested Capital-6.94-12.49-10.847.540.94-12.48-2.20-67.65-25.43
Quick Ratio0.951.161.251.211.341.811.600.300.76
Current Ratio1.481.731.851.621.742.571.860.300.76

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.12-10.66-19.66-17.2313.022.26-10.48-1.65-3.56
Depreciation5.184.974.153.573.482.290.950.230.00
Other Funds (Non Cash)2.162.07-0.4919.49-0.253.4113.85-2.322.88
Funds from Operations-6.09-5.84-19.704.7411.018.263.47-3.93-0.67
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.715.47-2.48-24.72-0.90-0.51-1.200.690.26
Cash from Operating Activities-0.38-0.36-22.18-19.9810.117.752.27-3.25-0.41
Capital Expenditures-1.07-1.03-1.30-0.71-5.88-4.34-6.06-7.90-0.03
Net Assets From Acquisitions-0.03-0.030.300.000.00-5.910.000.000.00
Sale of Fixed Assets and Businesses0.730.70-0.070.010.460.000.110.00-
Purchase or Sale of Investments-0.20-0.190.000.00-5.95-0.39-0.190.58-1.83
Purchase of Investments-0.20-0.190.000.00-5.95-0.39-0.19-0.80-1.83
Sale Or Maturity of Investments0.000.000.000.000.000.000.001.380.00
Other Uses-0.16-0.16-0.25-2.54-33.25-3.36-0.480.00-0.36
Other Sources0.060.063.783.060.000.000.000.000.00
Cash from Investing Activities-0.68-0.652.46-0.18-44.61-14.00-6.62-7.32-2.21
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.450.430.000.000.0042.4811.3017.890.52
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.450.430.000.000.0042.4811.3017.890.52
Proceedsfrom Stock Options0.450.430.000.000.0039.8511.0616.800.00
Issuance or Reduction of Debt, Net-14.30-6.993.57-15.5342.1521.18-3.78-0.092.43
Change in Long Term Debt-0.00------0.00
Issuance of Long Term Debt-0.00------0.00
Reduction of Long Term Debt-0.00------0.00
Net Financing Active Other Cash Flow0.000.009.160.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-0.030.000.000.000.000.000.00
Cash from Financing Activities-8.35-8.0111.25-16.8140.9962.867.3517.752.95
Exchange Rate Effect-0.01-0.01-0.010.082.13-1.400.06-0.460.00
Net Change in Cash-9.42-9.03-8.49-36.898.6255.213.076.710.33
Free Cash Flow-1.45-1.39-23.37-20.694.243.40-3.79-11.15-0.44
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----36.6879.90---
Deferred Taxes & Investment Tax Credit--2.21-3.70-1.10-5.240.30-0.84-0.190.00

Balance sheet, quarterly

Currency USD, millions
Metric2025S22025S12019S12018S12017S2
Cash & Short Term Investments15.2816.04-14.400.510.70
Short Term Receivables48.4749.45-1.200.020.01
Inventories35.2845.57-1.280.000.00
Other Current Assets0.36---0.000.00
Total Current Assets99.38111.06-16.880.520.71
Net Property, Plant & Equipment32.2631.19-4.130.000.00
Total Investments and Advances0.320.64-14.095.296.17
Intangible Assets68.7766.75-47.090.000.00
Deferred Tax Assets14.4311.87----
Other Assets0.000.00-0.000.000.00
Total Assets216.67223.24-82.195.826.89
Short Term Debt Incl. Current Port. of LT Debt32.6518.64-3.720.920.84
Accounts Payable21.3826.96-0.610.03-
Other Current Liabilities13.2314.38-0.410.230.10
Total Current Liabilities67.2659.98-4.741.190.94
Long Term Debt24.7734.62-0.160.000.00
Other Liabilities0.000.00-0.000.000.00
Total Liabilities92.3194.88-4.921.190.94
Non-Equity Reserves0.000.00-0.000.000.00
Preferred Stock - Carrying Value0.000.00-0.000.000.00
Common Equity124.41128.03-77.214.635.95
Total Shareholders Equity124.41128.03-77.214.635.95
Accumulated Minority Interest-0.050.33-0.060.000.00
Total Equity124.36128.36-77.274.635.95
Total Liabilities & Stockholders Equity216.67223.24-82.195.826.89
Book Value Per Share11.3813.57-16.061.271.69
Tangible Book Value Per Share5.096.50-6.261.271.69
Price to Book Ratio0.340.54----
Return on Assets-----33.58-
Return on Equity-----41.88-
Return on Invested Capital-6.89-0.29-9.38-28.54-13.83
Quick Ratio0.951.09-3.290.440.76
Current Ratio1.481.85-3.560.440.76

Cash flow, quarterly

Currency USD, millions
Metric2025S22025S12019S12018S12017S2
Net Income-10.62-0.50-7.26-1.32-0.82
Depreciation2.832.35-0.050.00-
Other Funds (Non Cash)2.48-0.33--8.941.240.68
Funds from Operations-7.601.52--1.63-0.08-
Extraordinary Item0.000.00-0.000.000.00
Changes in Working Capital6.20-0.49-0.63-0.070.01
Cash from Operating Activities-1.401.03--1.01-0.14-0.14
Capital Expenditures-0.17-0.90--3.590.000.00
Net Assets From Acquisitions-0.00-0.03-0.00-0.00
Sale of Fixed Assets and Businesses0.730.00-0.000.000.00
Purchase or Sale of Investments-0.200.00-0.70-0.03-0.00
Purchase of Investments-0.200.00--0.66-0.03-0.00
Sale Or Maturity of Investments0.000.00-1.36-0.00
Other Uses-0.160.00--0.170.000.00
Other Sources0.020.04-0.000.000.00
Cash from Investing Activities0.22-0.89--3.06-0.03-0.00
Cash Dividends Paid0.000.00-0.000.000.00
Preferred Dividends (Cash Flow)0.000.00-0.000.000.00
Change in Capital Stock0.040.42-17.550.000.00
Repurchase of Common Pref Stock0.000.00-0.000.000.00
Sale of Common Pref Stock0.040.42-17.550.00-
Proceedsfrom Stock Options0.040.42-0.000.000.57
Issuance or Reduction of Debt, Net-0.28-7.01--0.060.000.00
Change in Long Term Debt----0.000.00
Issuance of Long Term Debt----0.000.00
Reduction of Long Term Debt----0.000.00
Net Financing Active Other Cash Flow0.000.00-0.000.000.00
Other Financing Activities Uses0.000.00-0.000.000.00
Cash from Financing Activities-1.03-7.33-17.500.000.57
Exchange Rate Effect-0.01-0.00--0.250.00-0.03
Net Change in Cash-2.23-7.19-13.18-0.170.41
Free Cash Flow-1.570.12--4.60-0.14-0.14

Revenue breakdown

Israel2024: 64.56M 2025: 78.35M
Total Pharmaceutical Preparations revenue2024: 64.56M 2025: 78.35M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.06%0.0M7.9M22.29K
2026-10-150.06%0.0M7.2M21.73K
2026-09-300.06%0.0M7.2M22.12K
2026-09-150.08%0.0M7.2M25.06K
2026-08-310.11%0.0M7.2M25.87K
2026-08-140.03%0.0M7.2M9.30K
2026-07-310.03%0.0M7.2M9.44K
2026-07-150.03%0.0M7.2M11.45K
2026-06-300.04%0.0M6.8M10.97K
2026-06-150.14%0.0M6.8M8.41K
2026-05-290.09%0.0M6.3M6.44K
2026-05-150.07%0.0M8.0M7.83K
2026-04-300.08%0.0M8.0M8.74K
2026-04-150.02%0.0M8.0M7.91K
2026-03-310.05%0.0M8.0M10.96K
2026-03-130.05%0.0M8.0M18.89K
2026-02-270.05%0.0M8.0M18.74K
2026-02-130.01%0.0M8.0M16.35K
2026-01-300.01%0.0M8.0M15.82K
2026-01-150.01%0.0M8.0M15.08K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.001.951.375.8322.000.000.832-0.0630.002
call5.000.000.200.302.39355.000.000.319-0.0300.002
call7.500.000.750.003.7230.000.000.202-0.0360.002
call10.000.000.250.004.6620.000.000.176-0.0420.002
put2.500.000.750.007.2080.000.00-0.168-0.0620.002
put5.000.451.901.004.7826.000.00-0.713-0.0250.002
put7.502.804.400.006.5640.000.00-0.798-0.0350.002
put10.005.406.900.007.6350.000.00-0.824-0.0400.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-08-276-K/A2026-08-27SEC
2026-08-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-26SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-08-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-24SEC
2026-08-19DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-04SEC
2026-07-276-K/A2026-07-27SEC
2026-07-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-22SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-05-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-30SEC
2026-04-3020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-203Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-203Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-203Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-163Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-163Initial statement of beneficial ownership of securities2026-03-18SEC
2026-04-163Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-03SEC
2026-02-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-19SEC
2025-12-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-30SEC
2025-12-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-18SEC
2025-12-09SCHEDULE 13DSEC
2025-11-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-25SEC
2025-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-03SEC
2025-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-08SEC
2025-09-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-19SEC
2025-08-29UPLOADUpload SubmissionSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND0.36%
CITADEL ADVISORS LLC0.18%
MOORE CAPITAL MANAGEMENT, LP0.16%
RENAISSANCE TECHNOLOGIES LLC0.10%
Revisor Wealth Management LLC0.07%
Virtu Financial LLC0.04%
BlackRock, Inc.0.03%
GEODE CAPITAL MANAGEMENT, LLC0.03%
Atria Investments, Inc0.02%
Quent Capital, LLC0.02%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.03%

OakChart. INCR. Cached 15 minutes.

Some panels did not load: insider.